PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT) MARKET ANALYSIS

Peptide Receptor Radionuclide Therapy (PRRT) Market, by Drug Class (Lutetium (Lu-177), Yttrium-90, Indium-111, and others), By Disease Indication (Pancreatic - Neuroendocrine Tumor, Gastrointestinal Tract - Neuroendocrine Tumor and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : May 2023
Code : CMI2731
Pages :170
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

Global Peptide Receptor Radionuclide Therapy (PRRT) Market: Key Developments

March 2021, Novartis AG has announced that first interpretable results of the Phase III VISION study evaluating the efficacy and safety of 177Lu-PSMA-617, a targeted radioligand therapy in patients with metastatic, castration-resistant prostate cancer (mCRPC), which is prostate-specific membrane antigen (PSMA) positive.

June 2022, according to Cancer Treatment Centers of America, Peptide Receptor Radionuclide Therapy (PRRT) delivers high doses of radiation to tumors in the body to destroy or slow their growth and reduce disease side effects.

August 2022, U.S FDA approved the Enhertu (fam-trastuzumab-deruxtecan-nxki) IV infusion which is used to treat patient with HER2-low breast cancer.

On March 10, 2023, Pfizer Inc., American multinational pharmaceutical company has announced the U.S. Food and Drug Administration approved ZAVZPRET (zavegepant), the first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the acute treatment of migraine.